Abstract library

32 results for "Wiedenmann".
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#136 Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors
Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg
#213 Distinct Cut-Off Values of Ki-67-index for NET-Grading in a Large German Multicentrer Cohort
Introduction: Grading (G) of neuroendocrine tumors (NET) according to ENETS is based on immunhistochemical staining of Ki-67 antigen. Close margins between G1 and G2 NET often fail to differ in survival analysis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ulrich-Frank Pape
Authors: Rinke A, Maasberg S, Begum N, Baum R P, ...
#357 Alternative Splicing and Differential Gene Expression in Pancreatic NETs
Introduction: Alternative splicing is an important mechanism to increase diversity of the proteome in higher organisms. These protein isoforms can provide as a selective drug target or marker for cancer diagnosis.
We present here a new DNA array that allows identification of splice variation and differential expression of 357 G protein-coupled receptors (GPCR) and 11 proteins of the extracellular matrix.
Conference:
Category: Basic
Presenting Author: Jan Lennart Körner
#363 Clinicopathological characteristics are capable of predicting long-term outcome of gastrointestinal neuroendocrine tumours in Germany
Introduction: Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasm. Throughout the last decades the classification of NET has been both difficult and incoherent. Therefore making prognostic straticifation often difficult.
Conference:
Category: Basic
Presenting Author: Sebastian Maasberg
Keywords: outcome
#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel
#466 HIF-1a Determines the Metastatic Potential of the GEP-NET Cell Line BON-1
Introduction: Intratumoral hypoxia is a hallmark of solid tumor formation and a negative predictor of patient survival. Adaptation to hypoxia is mainly achieved by the transcription factor HIF-1a, which is upregulated in a diverse range of human and experimental tumors and their metastases. HIF-1a target genes have been implicated in the induction of invasion and metastasis. However, HIF-1a’s tumor-supporting action depends on cell type and microenvironment and the precise role of HIF-1a for the pathogenesis of neuroendocrine tumors (NET) is largely unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Katja Freitag de Molina
#529 Alternative Splicing and Differential Gene Expression in Pancreatic NETs
Introduction: Protein isoforms resulting from differentially spliced mRNA may constitute peculiar drug targets or markers for cancer diagnosis. We here present a new DNA array that allows identification of splice variation and differential expression for 357 G protein-coupled receptors (GPCR) and 11 proteins of the extracellular matrix.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Carsten Grötzinger
Keywords: pNET
#561 Determinants of Long-Term Outcome for Rectal NETs from a Large German Multicentre Cohort
Introduction: Neuroendocrine tumors (NET) of the rectum are a rare subgroup of NETs with mostly favorable prognosis. Some, however, tend to have a poorer outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Sebastian Maasberg